Sunshine Biopharma Inc. SEC filings

Filings

Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.

1. ROUTINEPRE 14CSunshine Biopharma Inc.SBFMW4d

   Sunshine Biopharma approves warrant provisions

   • Approved by Dr. Steve N. Slilaty, 89.5% voting power
   • Series D Warrants exercisable at $0.66 per share
   • Warrant stockholder approval effective 20 days after mailing
2. ROUTINE8-KSunshine Biopharma Inc.SBFMW4d

   Sunshine Biopharma approves stock issuance

   • Dr. Steve N. Slilaty approved issuing >20% of shares
   • Shares issued at discount to Nasdaq minimum price
   • Adjustments to Series D Warrants allowed
3. ROUTINESCHEDULE 13GSunshine Biopharma Inc.SBFMW5d

   Sunshine Biopharma Inc. 13G filing by BJI Financial Group

   • BJI Financial Group owns 6.0% of Sunshine Biopharma Inc.
   • Shares beneficially owned: 909,900
   • Filing date: 2026-10-14

   BJI Financial Group, filed by

4. ROUTINESCHEDULE 13GSunshine Biopharma Inc.SBFMW5d

   Sunshine Biopharma Inc. 9.9% held by CVI Investments

   • CVI Investments, Inc. holds 1,588,266 shares
   • 9.9% of total shares
   • Heights Capital Management, Inc. is investment manager

   CVI Investments, Inc., filed by

5. ROUTINE8-KSunshine Biopharma Inc.SBFMWOct 9

   Sunshine Biopharma Inc. raises $6M

   • Closed on 2026-10-09
   • Raised $6M before fees
   • Common Units at $0.55 each
6. ROUTINE424B4Sunshine Biopharma Inc.SBFMWOct 9

   Sunshine Biopharma Inc. offers $6M in units.

   • Up to 10,509,082 common units offered.
   • Each unit includes 1 share and 2 Series D warrants.
   • Up to 400,000 pre-funded units offered.
7. ROUTINEEFFECTSunshine Biopharma Inc.SBFMWOct 8

   Sunshine Biopharma Inc. files S-1 form

   • Filed on October 7, 2026
   • Form S-1 submitted
   • CIK 0001402328
8. ROUTINESCHEDULE 13G/ASunshine Biopharma Inc.SBFMWOct 5

   Sunshine Biopharma Inc. reports 4.9% stake

   • Alta Partners LLC owns 200,000 shares
   • 4.9% of total shares
   • Filing date: 2026-10-05

   Alta Partners LLC

9. NOTABLES-1Sunshine Biopharma Inc.SBFMWOct 2

   Sunshine Biopharma files S-1

   • Filed S-1 on 2026-10-02
   • Up to $7M offering
   • Common Units with 2 Series D Warrants
10. ROUTINEDEF 14CSunshine Biopharma Inc.SBFMWSep 28

    DEF 14C filing

11. ROUTINEDRSSunshine Biopharma Inc.SBFMWSep 24

    DRS filing

12. ROUTINEPRE 14CSunshine Biopharma Inc.SBFMWSep 16

    PRE 14C filing

13. ROUTINE8-KSunshine Biopharma Inc.SBFMWSep 16

    Current report

14. ROUTINE8-KSunshine Biopharma Inc.SBFMWSep 11

    Current report

15. ROUTINEEFFECTSunshine Biopharma Inc.SBFMWSep 9

    Registration declared effective

16. ROUTINE424B3Sunshine Biopharma Inc.SBFMWSep 8

    Securities offering

17. NOTABLES-1Sunshine Biopharma Inc.SBFMWAug 28

    Securities offering

18. ROUTINE8-KSunshine Biopharma Inc.SBFMWAug 28

    Current report

19. ROUTINESCHEDULE 13G/ASunshine Biopharma Inc.SBFMWAug 14

    Ownership stake disclosure by L1 Capital Global Opportunities Master Fund, Ltd. (amended)

    L1 Capital Global Opportunities Master Fund, Ltd., filed by

20. NOTABLE10-QSunshine Biopharma Inc.SBFMWAug 13

    Quarterly report

21. ROUTINESCHEDULE 13G/ASunshine Biopharma Inc.SBFMWAug 13

    Ownership stake disclosure by INTRACOASTAL CAPITAL, LLC (amended)

    INTRACOASTAL CAPITAL, LLC, filed by

22. ROUTINE4Sunshine Biopharma Inc.SBFMWAug 11

    David Natan, insider filing for SBFMW

    David Natan, reporting

23. ROUTINE8-KSunshine Biopharma Inc.SBFMWAug 3

    Current report

24. ROUTINE424B5Sunshine Biopharma Inc.SBFMWJul 20

    Securities offering

25. ROUTINE8-KSunshine Biopharma Inc.SBFMWJul 20

    Current report

26. ROUTINE8-KSunshine Biopharma Inc.SBFMWJul 10

    Current report

27. ROUTINESCHEDULE 13GSunshine Biopharma Inc.SBFMWJul 8

    Ownership stake disclosure by Alta Partners LLC

    Alta Partners LLC, filed by

28. ROUTINEDEF 14CSunshine Biopharma Inc.SBFMWJun 8

    DEF 14C filing

29. ROUTINEPRE 14CSunshine Biopharma Inc.SBFMWMay 29

    PRE 14C filing

30. ROUTINE8-KSunshine Biopharma Inc.SBFMWMay 29

    Current report

31. ROUTINESCHEDULE 13GSunshine Biopharma Inc.SBFMWMay 22

    Ownership stake disclosure by L1 Capital Global Opportunities Master Fund, Ltd.

    L1 Capital Global Opportunities Master Fund, Ltd., filed by

32. ROUTINESCHEDULE 13GSunshine Biopharma Inc.SBFMWMay 21

    Ownership stake disclosure by BIGGER CAPITAL FUND L P

    BIGGER CAPITAL FUND L P, filed by

33. ROUTINE8-KSunshine Biopharma Inc.SBFMWMay 19

    Current report

34. ROUTINE424B4Sunshine Biopharma Inc.SBFMWMay 19

    Securities offering

35. ROUTINEEFFECTSunshine Biopharma Inc.SBFMWMay 19

    Registration declared effective

36. NOTABLE10-QSunshine Biopharma Inc.SBFMWMay 13

    Quarterly report

37. NOTABLES-1Sunshine Biopharma Inc.SBFMWMay 12

    Securities offering

38. ROUTINE4Sunshine Biopharma Inc.SBFMWApr 14

    David Natan, insider filing for SBFMW

    David Natan, reporting

39. ROUTINE8-KSunshine Biopharma Inc.SBFMWApr 9

    Current report

40. NOTABLE10-KSunshine Biopharma Inc.SBFMWApr 3

    Annual report

41. NOTABLENT 10-KSunshine Biopharma Inc.SBFMWMar 31

    Late annual report notice

42. ROUTINE8-KSunshine Biopharma Inc.SBFMWMar 9

    Current report

43. ROUTINEDEF 14CSunshine Biopharma Inc.SBFMWMar 2

    DEF 14C filing

44. ROUTINE8-KSunshine Biopharma Inc.SBFMWFeb 20

    Current report

45. ROUTINEPRE 14CSunshine Biopharma Inc.SBFMWFeb 20

    PRE 14C filing

46. ROUTINE8-KSunshine Biopharma Inc.SBFMWFeb 5

    Current report

47. ROUTINE8-KSunshine Biopharma Inc.SBFMWDec 12, 2025

    Current report

48. NOTABLE10-QSunshine Biopharma Inc.SBFMWNov 13, 2025

    Sunshine Biopharma Inc. (SBFMW) filed its Q3 2025 quarterly report (Form 10-Q), providing investors with an update on the company's financial performance and operational activities.

Older filings on EDGAR